Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech
NEW YORK, Sept. 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech
http://www.reportlinker.com/p01181004/Preclinical-Stage-Partnering-Terms-and-Agreements-in-Pharma-and-Biotech.html
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest preclinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all preclinical stage partnering deals announced since 2009 including financial terms where available including over 2,000 links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
This report is formatted to allow direct access to each contract document by deal type agreed by each company listed. Each deal title is linked to an online version of the contract document as filed by the parties with the Securities Exchange Commission.
The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.
Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.
Chapter 5 provides a review of trends in preclinical stage deal making since 2009. Deals are listed by big pharma and big biotech dealmaking in preclinical stage, deal type, therapy type and technology type.
Chapter 6 provides a detailed analysis of preclinical stage payment terms including average headline, upfront, milestone and royalty rates for preclinical deals.
Chapter 7 provides a review of the leading preclinical stage deal by headline value.
Chapter 8 provides a comprehensive listing of the top 50 big pharma and top 50 big biotech companies with a brief summary followed by a comprehensive listing of preclinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2009 organized by stage of development – preclinical.
The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2009.
In addition, a comprehensive appendix is provided organized by partnering company A-Z , deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:
In-depth understanding of preclinical stage deal trends since 2009
Access to headline, upfront, milestone and royalty data
Comprehensive access to over 2,000 preclinical stage deals together with contract documents if available
Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
Analysis of the structure of preclinical stage agreements with numerous real life case studies
Identify leading preclinical stage deals by value since 2009
Identify the most active preclinical stage dealmakers since 2009
Full listing of preclinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Why do companies partner preclinical stage compounds?
2.1. Introduction
2.2. The role of preclinical stage partnering
2.2.1. In-licensing at preclinical stage
2.2.2. Out-licensing at preclinical stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into preclinical stage partnering deals
2.4.1. Licensors reasons for entering preclinical stage deals
2.4.2. Licensees reasons for entering preclinical stage deals
2.5. The future of preclinical stage partnering deals
Chapter 3 – Preclinical stage deal strategies and structure
3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical / biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Pfizer - Repligen
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Roche – Genentech - Chiasma
3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter – Onconova Therapeutics
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on preclinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure preclinical stage licensing agreements
3.6.1.a. Case study : Merck and Co. – Tesaro
3.6.1.b. Case study : Marina Biotech – Mirna Therapeutics
3.7. Multicomponent preclinical stage partnering agreements
3.7.1. Example multicomponent preclinical stage clauses
3.7.1.a. Case study: Eleven Biotherapeutics – ThromboGenics
3.7.1.b. Case study: Pfizer – InSite Vision
Chapter 4 – Preclinical stage partnering payment strategies
4.1. Introduction
4.2. Preclinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments
Chapter 5 – Trends in preclinical stage deal making
5.1. Introduction
5.2. Preclinical stage partnering over the years
5.2.1.. Attributes of preclinical deals
5.3. Big pharma preclinical stage dealmaking activity
5.4. Big biotech preclinical stage dealmaking activity
5.5. Preclinical stage partnering by deal type
5.6. Preclinical stage partnering by disease type
5.7. Partnering by preclinical stage technology type
Chapter 6 – Average payment terms for preclinical stage partnering
6.1. Introduction
6.2. Guidelines for preclinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Preclinical stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Preclinical stage headline values
6.4.2. Preclinical stage upfront payments
6.4.3. Preclinical stage milestone payments
6.4.4. Preclinical stage royalty rates
Chapter 7 – Leading preclinical stage deals
7.1. Introduction
7.2. Top preclinical stage deals by value
Chapter 8 – Big pharma and big biotech preclinical stage partnering deals
8.1. Introduction
8.2. How to use big pharma/big biotech preclinical stage partnering deals
8.3. Big pharma preclinical stage partnering company profiles
Abbott
Abbott Molecular
Abbvie
Actavis
Actavis (acquired by Watson)
Watson Pharmaceuticals
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Bayer Healthcare
Bayer Schering Pharma
Bayer Vital
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
CSL Biotherapies
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Janssen Biotech
Janssen Research & Development
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck Sharpe & Dohme
Merck KGaA
Merck Serono
Mitsubishi Tanabe
Novartis
Novartis Animal Health
Novartis Venture Funds
Novo Nordisk
Otsuka
Pfizer
Pfizer Animal Health
Roche
Roche Diagnostics
Genentech
Sanofi
Sanofi US Services
Sanofi-Aventis
Sanofi-Pasteur
Servier
Shionogi
Shire
Shire Human Genetic Therapies
Takeda
Teva
UCB
Valeant
8.4. Big biotech preclinical stage partnering company profiles
3SBio
Acorda Therapeutics
Actelion
Alexion Pharmaceuticals
Alkermes
Array Biopharma
Bavarian Nordic
Biocon
BioMarin Pharmaceuticals
Cubist
Dendreon
Elan
Emergent BioSolutions
Enzo Biochem
Galapagos
Genmab
Ipsen
Isis Pharmaceuticals
LFB Group
Morphosys
Nektar Therapeutics
NPS Pharmaceuticals
Onyx Pharmaceuticals
Optimer
Regeneron Pharmaceuticals
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
United Therapeutics
Vertex Pharmaceuticals
ViroPharma
Chapter 9 – Preclinical stage partnering contracts directory
9.1. Introduction
9.2. Company A-Z
9.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Manufacturing - OEM
Marketing
Material transfer
Option
Promotion
Research
Settlement
Sub-license
Supply
Technology transfer
Termination
9.4. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
9.5. By therapy area
9.6. By technology type
Analysis
Animal models
Antibiotics
Macrolides
Tetracycline
Antibodies
Antibody-drug conjugate
Bispecific antibodies
Monoclonal antibodies
Humanized mAb
Human mAb
Murine mAb
Assays
Biodefense
Biological compounds
Biomarkers
Biomaterials
Biosimilars/Bio-betters
Clinical testing
Devices
Diagnostics
Companion
Ultrasound
Molecular diagnostics
Discovery tools
Compound screening library
DNA probes
Drug delivery
Implantable
Oral delivery
Delayed release
Injectable
Targeted
Topical
Transmucosal
Nasal
Ocular
Enabling technology
Epigenetics
Gene therapy
Genomics
Implant
In vitro models
Microarray
Nanotechnology
Natural product
Oligonucleotide
Peptides
Personalised medicine
Pharmacogenomics
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Cell therapy
Stem cells
Research services
RNA therapeutics
Screening
Small molecules
Toxicity
Vaccines
Chapter 10 – Preclinical stage dealmaking directory
10.1. Introduction
10.2. Preclinical stage deals by year
Preclinical stage deals - 2014
Preclinical stage deals - 2013
Preclinical stage deals - 2012
Preclinical stage deals - 2011
Preclinical stage deals - 2010
Preclinical stage deals - 2009
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering
Order Form – Upgrades to subscription access products
Order Form – Reports
View the accompanying volume for:
Appendices
Introduction
Appendix 1 – Directory of preclinical stage deals by company A-Z 2009-2014
Appendix 2 – Directory of preclinical stage deals by deal type 2009-2014
Appendix 3 – Directory of preclinical stage deals by therapy area 2009-2014
Appendix 4 – Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking
Table of figures
Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2009-2014), % of all deals
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for preclinical stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Preclinical stage partnering frequency 2009-2014
Figure 7: Big pharma – top 50 – preclinical stage deals 2009 to 2014
Figure 8: Big pharma preclinical stage deal frequency – 2009 to 2014
Figure 9: Big biotech – top 50 – preclinical stage deals 2009 to 2014
Figure 10: Big biotech preclinical stage deal frequency – 2009 to 2014
Figure 11: Preclinical stage partnering by deal type since 2009
Figure 12: Preclinical stage partnering by disease type since 2009
Figure 13: Preclinical stage partnering by technology type since 2009
Figure 14: Review of upfront payments for preclinical stage deals 2009-2014
Figure 15: Review of milestone payments for preclinical stage deals 2009-2014
Figure 16: Review of royalty payments for preclinical stage deals 2009-2014
Figure 17: Preclinical stage deals with a headline value – 2009
Figure 18: Preclinical stage deals with a headline value – 2010
Figure 19: Preclinical stage deals with a headline value – 2011
Figure 20: Preclinical stage deals with a headline value – 2012
Figure 21: Preclinical stage deals with a headline value – 2013
Figure 22: Preclinical stage deals with a headline value – 2014
Figure 23: Pre clinical stage deal headline value distribution, US$million
Figure 24: Summary median headline value for preclinical stage of development, 2009-2014
Figure 25: Preclinical stage deals with upfront payment values - 2009
Figure 26: Preclinical stage deals with upfront payment values - 2010
Figure 27: Preclinical stage deals with upfront payment values - 2011
Figure 28: Preclinical stage deals with upfront payment values - 2012
Figure 29: Preclinical stage deals with upfront payment values - 2013
Figure 30: Preclinical stage deals with upfront payment values - 2014
Figure 31: Pre clinical stage deal upfront value distribution, US$million
Figure 32: Summary median upfront payments preclinical stage of development, 2009-2014
Figure 33: Preclinical stage deals with milestone payments - 2009
Figure 34: Preclinical stage deals with milestone payments - 2010
Figure 35: Preclinical stage deals with milestone payments - 2011
Figure 36: Preclinical stage deals with milestone payments - 2012
Figure 37: Preclinical stage deals with milestone payments - 2013
Figure 38: Preclinical stage deals with milestone payments - 2014
Figure 39: Summary median milestone payments for preclinical stage of development, 2009-2014
Figure 40: Preclinical stage deals with royalty rates, % - 2009
Figure 41: Preclinical stage deals with royalty rates, % - 2010
Figure 42: Preclinical stage deals with royalty rates, % - 2011
Figure 43: Preclinical stage deals with royalty rates, % - 2012
Figure 44: Preclinical stage deals with royalty rates, % - 2013
Figure 45: Preclinical stage deals with royalty rates, % - 2014
Figure 46: Summary median royalty rate for preclinical stage of development, 2009-2014
Figure 47: Top preclinical stage deals by value since 2009
To order this report: Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech
http://www.reportlinker.com/p01181004/Preclinical-Stage-Partnering-Terms-and-Agreements-in-Pharma-and-Biotech.html
_________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article